PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26416458-0	2015	KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.	Platinum	95-103	KRAS proto-oncogene, GTPase	Homo sapiens	0-4	
26416458-2	2015	The aim of this planned ancillary study within the TAILOR trial was to assess the prognostic value of KRAS mutations in advanced NSCLC patients treated with platinum-based first-line chemotherapy.	Platinum	157-165	KRAS proto-oncogene, GTPase	Homo sapiens	102-106	
26416458-6	2015	This study, with all consecutive patients genotyped, indicates that the presence of KRAS mutations has a mild negative impact on OS in advanced NSCLC patient treated with a first-line platinum-containing regimen.	Platinum	184-192	KRAS proto-oncogene, GTPase	Homo sapiens	84-88